U.S. Third Circuit Rejects Claims of Preemption and Allows Fosamax Cases to Proceed

In 2022, over 500 plaintiffs filed a case alleging that Merck Sharp & Dohme Corp., a drug manufacturing company, failed to provide adequate warnings that one of their drugs increased the risk of atypical femoral fractures….
By: Fishman Haygood LLP